We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
265
Reports published
10k+
Readers in database
Ph I data for ultra-conc rapid-acting #insulin #AT278 showed superior PK/PD profile vs NovoRapid supporting potential to address both prandial & high insulin requiring #diabetes markets & lower adoption barriers to insulin pumps. For more on @arecor_ltd: https://www.trinitydelta.org/companies/arecor-therapeutics/
Our @arecor_ltd initiation explores its #formulation expertise & pipeline of clinical assets with enhanced properties. Proceeds from its June #AIM #IPO take $AREC thru several value inflection points over the next 18-24m
https://www.trinitydelta.org/companies/arecor-therapeutics/
SANOVO, the 1st of 2 China Phase III #savolitinib + #Tagrisso combo studies in #NSCLC, has initiated. @hutchmed & @AstraZeneca also due to start SACHI (EGFR-TKI refractory MET+ NSCLC) in H221. $HCM
1st in class #ROCK2 inhibitor #Rezurock is central to @sanofi's $1.9bn all cash acquisition of #Kadmon. @RedxPharma's #RXC007 is the only other ROCK2 inhibitor in the clinic: Ph I data expected H122.
For more on $REDX.L see: https://www.trinitydelta.org/companies/redx-pharma/
Continued progress of pan-RAF inhibitor prog JZP815, evidenced by a $3m milestone from @JazzPharma, further solidifies @RedxPharma's financial foundation, supporting higher R&D spend thru several value inflection points to end-2022. Read more on $REDX.L: https://www.trinitydelta.org/companies/redx-pharma/
Strong H121 performance, despite COVID-19 headwinds, reassures that execution on @NexstimOyj's 2020-24 growth strategy is delivering commercial traction with its @SmartfocusTMS technology.
Read our Outlook note: https://www.trinitydelta.org/companies/nexstim/
Please sign up here to be added to our distribution database
';